Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of Programmed Death Ligand 1 Expression on Outcomes in Stage I-II Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma.

Clinical lung cancer - 1 May 2026

Murakami Kotaro, Shimada Yoshihisa, Hamaji Masatsugu, Yamanashi Keiji, Kawaguchi Yohei, Kudo Yujin, Kayawake Hidenao, Yutaka Yojiro, Date Hiroshi, Ikeda Norihiko

Abstract excerpt

BACKGROUND: We aimed to investigate the clinicopathological characteristics and prognostic significance of programmed death ligand 1 (PD-L1) expression in patients with pathological stage I-II epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD) undergoing surgical resection. PATIENTS AND METHODS: Patients with EGFR-mutant LUAD who underwent complete surgical resection between 2017 and 2019...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to ErbB Receptors

Share to Neoplasm Recurrence, Local

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Survival Rate

Source

Identifiers

PMID: 42055887
DOI: 10.1016/j.cllc.2026.03.013

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of Programmed Death Ligand 1 Expression on Outcomes in Stage I-II Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinoma.PMID 42055887Read ↗

Prognostic impact of PD-L1 expression in surgically resected EGFR-mutant lung adenocarcinoma: A real-world database study in Japan (CReGYT-01 EGFR study).Semantic proximity Read ↗

Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.Semantic proximity Read ↗

Expression and clinical significance of programmed cell death protein 1/programmed death-ligand 1 in non-small cell lung cancer patients with rare mutations of epidermal growth factor receptor gene: A retrospective cohort studySemantic proximity Read ↗

PD-L1 expression is not a predictive factor for recurrence in resected non-small cell lung cancer Sub-heading: PD-L1 is not a predictive factor for recurrenceSemantic proximity Read ↗

Significance of programmed death-ligand 1 expression in resected lung cancer and its relationship with EGFR mutation.Semantic proximity Read ↗

PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.Semantic proximity Read ↗

Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.Semantic proximity Read ↗

Relationship of tumor PD-L1 expression with<i>EGFR</i>wild-type status and poor prognosis in lung adenocarcinomaSemantic proximity Read ↗

Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

PD-L1 Expression and Histopathological Features in EGFR-Mutated Non-Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After EGFR-Tyrosine Kinase Inhibitors Resistance.Semantic proximity Read ↗

Clinical and molecular characteristics associated with high PD-L1 expression in EGFR-mutated lung adenocarcinoma.Semantic proximity Read ↗

PD-L1 expression is associated with inferior outcomes independent of EGFR subtype in advanced non-small cell lung cancer with uncommon EGFR mutations treated with first-line second-generation EGFR-tyrosine kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.